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In Rspondin-based 3D cultures, Lgr5 stem cells
from multiple organs form ever-expanding epithelial
organoids that retain their tissue identity. We report
the establishment of tumor organoid cultures from
20 consecutive colorectal carcinoma (CRC) patients.
For most, organoids were also generated from adja-
cent normal tissue. Organoids closely recapitulate
several properties of the original tumor. The spec-
trum of genetic changes within the ‘‘living biobank’’
agrees well with previous large-scale mutational
analyses of CRC. Gene expression analysis indicates
that the major CRC molecular subtypes are repre-
sented. Tumor organoids are amenable to high-
throughput drug screens allowing detection of
gene-drug associations. As an example, a single
organoid culture was exquisitely sensitive to Wnt
secretion (porcupine) inhibitors and carried a muta-
tion in the negative Wnt feedback regulator RNF43,
rather than in APC. Organoid technology may fill
the gap between cancer genetics and patient trials,
complement cell-line- and xenograft-based drug
studies, and allow personalized therapy design.
INTRODUCTION
Colorectal carcinoma (CRC) represents one of the major forms
of cancer. Seminal studies have revealed a series of molecularpathways that are critical to the pathogenesis of CRC,
including WNT, RAS-MAPK, PI3K, P53, TGF-b, and DNA
mismatch repair (Fearon, 2011; Fearon and Vogelstein,
1990). Large-scale sequencing analyses have dramatically
extended the list of recurrently mutated genes and chromo-
somal translocations (Garraway and Lander, 2013; Vogelstein
et al., 2013). CRC cases are characterized by either microsat-
ellite instability (MSI) (associated with a hyper-mutator pheno-
type), or as microsatellite-stable (MSS) but chromosomally
unstable (CIN) (Lengauer et al., 1997). The absolute number
and combination of genetic alterations in CRC confounds our
ability to unravel the functional contribution of each of these
potential cancer genes. Thus, while genome changes in tu-
mors of individual patients can be assessed in great detail
and at low cost, these data are difficult to interpret in terms
of prognosis, drug response, or patient outcome, necessi-
tating model systems for analysis of genotype-to-phenotype
correlations.
Self-renewal of the intestinal epithelium is driven by Lgr5
stem cells located in crypts (Barker et al., 2007). We have
recently developed a long-term culture system that maintains
basic crypt physiology (Sato et al., 2009). Wnt signals are
required for the maintenance of active crypt stem cells (Korinek
et al., 1998; Kuhnert et al., 2004; Pinto et al., 2003). Indeed, the
Wnt agonist R-spondin1 induces dramatic crypt hyperplasia
in vivo (Kim et al., 2005). R-spondin-1 is the ligand for Lgr5 (Car-
mon et al., 2011; de Lau et al., 2011). Epidermal growth factor
(EGF) signaling is associated with intestinal proliferation
(Wong et al., 2012), while transgenic expression of Noggin
induces a dramatic increase in crypt numbers (Haramis et al.,
2004). The combination of R-spondin-1, EGF, and Noggin inCell 161, 933–945, May 7, 2015 ª2015 Elsevier Inc. 933
Basement Membrane Extract (BME) sustains ever-expanding
small intestinal organoids, which display all hallmarks of the
original tissue in terms of architecture, cell-type composition,
and self-renewal dynamics. We adapted the culture condition
for long-term expansion of human colonic epithelium and
primary colonic adenocarcinoma, by adding nicotinamide,
A83-01 (Alk inhibitor), Prostaglandin E2, and the p38 inhibitor
SB202190 (Sato et al., 2011). Of note, a 2D culture method
for cells from normal and malignant primary tissue has been
described by Liu et al. (2012).
Here, we explore organoid technology to routinely establish
and phenotypically annotate ‘‘paired organoids’’ derived from
adjacent tumor and healthy epithelium from CRC patients.
RESULTS
Establishment of a Living CRC Biobank
Surgically resected tissue was obtained from previously
untreated CRC patients. Tissue from rectal cancer patients
was excluded because they routinely undergo irradiation before
surgery. For multiple tissues, we observe that normal tissue-
derived organoids outcompete tumor organoids under the opti-
mized culture conditions, presumably due to genomic instability
and resulting apoptosis in the latter. Combination of Wnt3A
and the Wnt amplifier R-spondin1 is essential to grow organoids
from normal epithelium. Over 90% of CRC cases harbor muta-
tions that aberrantly activate the Wnt signaling pathway (Cancer
Genome Atlas Network, 2012), so we exploited the Wnt-depen-
dency of normal colonic stem cells to selectively expand tumor
organoids. A total of 22 tumor organoid cultures and 19
normal-adjacent organoid cultures were derived from 20 pa-
tients (P19 and P24 each carried two primary tumors separated
by >10 cm; Figure 1A). We successfully generated organoid
cultures from 22 of 27 tumor samples. For one, we never
observed growth. Four were lost due to bacterial/yeast infection.
Since then, we have added next-generation antibiotics (see
Experimental Procedures) and currently observe an 90%
success rate.
The number of primary tumor organoids varied between
patient samples, with some tumors rendering thousands of
primary organoids whereas others yielded only 10–20 primary
organoids. This difference in derivation likely reflects the hetero-
geneous composition of tumors, with proliferative areas inter-
mingled with regions of differentiated cells, stromal cells or
necrosis. The growth rate of the organoids from patients 5 and
27 decreased over time, which prohibited their inclusion in the
drug screen. All other organoids could be readily expanded
and frozen to create a master cell bank. Upon thawing, cell
survival was typically >80%. Unlike healthy tissue-derived
organoids, tumor-derived organoids presented with a range of
patient-specific morphologies, ranging from thin-walled cystic
structures to compact organoids devoid of a lumen. H&E
staining on primary tumors and the corresponding organoids
revealed that the ‘‘cystic versus solid’’-organization of the
epithelium was generally preserved. Yet, marker expression
analysis (KI67, OLFM4, KRT 20, Alcian blue) revealed hetero-
geneity both between patients and individual organoids within
each culture (Figure 1B; Data S1).934 Cell 161, 933–945, May 7, 2015 ª2015 Elsevier Inc.Genomic Characterization of Tumor-Derived Organoids
Genomic DNA was isolated from tumor and matched normal
organoid cultures for whole-exome sequencing in order to iden-
tify tumor-specific somatic mutations (Cancer Genome Atlas
Network, 2012). Genomic DNA from the corresponding biopsy
specimens were available for comparative analysis for 16 of
these cases (Table S1A). The mutation rates per Mb varied
widely for different tumor organoids (range 2.0–77.9), with a me-
dian value of 3.7 in the tumor organoids, similar to the median
rate of 3.6 in the biopsy samples (Figure 2A; Table S1B). Muta-
tions were predominantly CpG to T transitions, consistent with
results from large-scale CRC sequencing (Figures S1A and
S1B; Table S1C). Of the 22 tumor organoids, six displayed
hypermutation (>10 mutations/Mb): P7, P10 and the organoids
from the two patients with two tumors each (P19a and P19b,
P24a and P24b). Interestingly, the P19a and P19b tumors share
TP53 R273C and BRAF V600E alterations, suggesting they
arose from the same somatically altered progenitor cell but
then diverged to acquire independent secondary alterations
(Figures S1C and S1D). In contrast, the P24a and P24b tumors
share 80% (469/590) of somatic alterations but then have discor-
dant driving alterations in APC and TP53, indicating that the
hypermutator phenotype may have been present prior to the
acquisition of growth promoting mutations (Figures S1E and
S1F). The frequency of hypermutated organoid cultures in our
patient panel (20%; 4 of 20) agreed with the reported frequency
in a much larger cohort of clinical samples and display compara-
ble somatic copy number alterations (SCNAs) (Figure 2B; Table
S1D) (Bass et al., 2011; Cancer Genome Atlas Network, 2012).
The successful derivation of both hypermutated and non-hyper-
mutated organoids implies an absence of culture-based bias.
Somatic variants within the coding regions in organoid
cultures were highly concordant with the corresponding biopsy
specimen for both hypermutated and non-hypermutated
patients (median = 0.88 frequency of concordance, range
0.62–1.00) (Figure 3A; Table S1E). Indeed, combined analysis
of SCNAs and single nucleotide variants (SNVs) to infer Cancer
Cell Fractions (CCF) (Carter et al., 2012; Landau et al., 2013) in
the biopsy and tumor organoids, revealed that the common
CRC driver mutations were maintained in culture. In 13 out of
14 organoid-biopsy pairs tested, tumor subclones sharing com-
mon CRC drivers were detected in the biopsy. In 50% of the
organoids, a dominant subclone from the biopsy was present,
likely representing sampling during derivation but it could also
indicate loss in culture (Figures S2A and S2B; Tables S1F and
S1G). Transcriptome analysis of single organoids showed subtle
differences in gene expression within an organoid culture,
confirming their heterogeneous composition. The differences
in overall gene expression were more pronounced in the organo-
ids derived from the hypermutant tumors (Figure S2C).
Discordant mutations were assessed for their likely biological
significance in cancer, based on Cancer Gene Census and data
reported from the PanCancer analysis of 5,000 whole exomes
(Futreal et al., 2004; Lawrence et al., 2014). Only 4% (27/679)
of discordant mutations found in organoids affected cancer-
related genes, including a third hit to APC, which was already
biallelically inactivated in P14, SMAD4 mutation in P16, and
POLE mutation in P19b (Table S1H). Cancer-significant genes
Figure 1. Derivation of Organoids from Primary Tissue
(A) Overview of the procedure. A total of 22 tumor organoids and 19 normal control organoids were derived and analyzed by exome-sequencing, RNA expression
analysis and high-throughput drug screening. To determine the concordance between tumor organoids and primary tumor, DNA from the primary tumor was also
isolated.
(B) Organoids architecture resembles primary tumor epithelium. H&E staining of primary tumor and the tumor organoids derived of these. A feature of most
organoids is the presence of one or more lumens, resembling the tubular structures of the primary tumor (e.g., P8 and P19b). Tumors devoid of lumen give rise to
compact organoids without lumen (P19a). Scale bar, 100 mM.
See also Data S1.that were discordant in the biopsy represented 4.4% (12/271)
(Table S1H). The discordant mutations had a mean allelic fre-
quency of 10.3% and 34.1% for the biopsy and organoids,
respectively. This could represent the enrichment or depletion
of a sub-clonal population in the organoid culture present withinthe original tumor, as well as acquisition of additional mutations
during derivation or propagation.
The most commonly altered genes in CRC (Bass et al., 2011;
Cancer Genome Atlas Network, 2012; Lawrence et al., 2014)
were well represented in the organoid cultures (Figure 3B;Cell 161, 933–945, May 7, 2015 ª2015 Elsevier Inc. 935
Figure 2. CRC Subtypes Are Present in
Organoid Cultures
(A) Whole exome sequencing of the tumor and
corresponding biopsy, when available, revealed
the presence of hypermutated (>10mutations/Mb)
and non-hypermutated subtypes within the orga-
noids. Comparable rates of mutations were
observed in the tumor organoid (O) and tumor
biopsy (B). Organoids without corresponding
biopsy are indicated in with red (O).
(B) Comparison of somatic copy-number alter-
ations found in the biopsies and corresponding
organoids (Biop/Org) and TCGA CRC in hyper-
mutated and non-hypermutated samples.
See also Figure S1 and Tables S1A–S1D.Tables S1I and S1J). Inactivating alterations to the tumor sup-
pressors APC, TP53, FBXW7, and SMAD4, as well as activating
mutations in KRAS (codon 12 and 146) and PIK3CA (codon
545 and 1047) were observed. Activating mutations in BRAF
and TGFBR1/2 mutations were observed in the hypermutated
organoids, consistent with previous reports for primary CRC
(Cancer Genome Atlas Network, 2012).
Mutations of genes in DNA mismatch repair (MMR)-associ-
ated pathways are associated with a hypermutated phenotype
(Boland and Goel, 2010). Consistent with their classification as
hypermutated CRC cases (Cancer Genome Atlas Network,
2012), missense mutations were present in MSH3 in P7, and
POLE mutations were detected in P10, P19a, and P19b. We
did not observe mutations in MMR-associated genes in P24a
and P24b and expression analysis showed normal levels of the
pertinent genes. The culprit for hyper mutability thus remains
to be identified for P24. The limited cohort size did not allow a
statistical analysis for somatic copy number alterations to iden-
tify significant regions of amplification and deletions. However,
manual inspection of the top regions identified by TCGA did
reveal the presence of ERBB2-,MYC-, and IGF2-amplified orga-
noids, as well as a reported gain of 13q in the non-hypermutated
group (Figure 3C) In aggregate, these analyses demonstrate
that organoid cultures faithfully capture the genomic features
of the primary tumor from which they derive and much of the
genomic diversity of CRC.
Most CRC cases carry activating mutations in the WNT
pathway: inactivation mutations in APC, FBXW7, AXIN2, and
FAM123B, or activating mutations in CTNNB1 (Cancer Genome
Atlas Network, 2012). Gene fusions involving the Wnt-agonistic
RSPO2 and RSPO3 genes have been observed in 5%–10%
of CRC (Seshagiri et al., 2012). RNF43 encodes a negative
regulator of the Wnt pathway, which serves to remove the
Wnt receptor FZ in a negative feedback loop (Hao et al.,
2012; Koo et al., 2012, de Lau et al., 2014). Recent sequencing
efforts of gastric, ovary, and pancreatic neoplasias identified
RNF43 mutations (Jiao et al., 2014; Ryland et al., 2013; Wang
et al., 2014), and RNF43 mutations have been observed in936 Cell 161, 933–945, May 7, 2015 ª2015 Elsevier Inc.CRC (Giannakis et al., 2014; Ivanov
et al., 2007; Koo et al., 2012)
We found APC alterations in all but
four of the organoids (P11, P19a/b,P28). Western blotting revealed P11 to express a truncated
APC protein, pointing to a mutational event not covered by our
exome-sequencing (Figure S3). The wtAPC organoid P28 carries
an activating mutation in CTNNB1 (T41A). In both P19a and
P19b, we detected RNF43mutations: frameshifts at aa positions
659 and 355, respectively. Only the latter is predicted to affect
protein function.
RNA Analysis of Normal and Tumor-Derived Organoids
Organoid cultures consist purely of epithelial cells. Therefore, the
system allows for direct gene expression analysis without a
contamination from mesenchyme, blood vessels, immune cells,
etc. Normal colon-derived and tumor-derived organoids were
plated under identical conditions in complete medium (+Wnt).
After 3 days, RNA was analyzed using Affymetrix single tran-
script arrays. Figure 4A shows the correlation heatmap of the
organoid samples. Normal colon-derived organoids clustered
tightly together, while the tumor-derived organoids exhibited
muchmore heterogeneity. Next, we searched for genes differen-
tially expressed between normal and tumor organoids. Normal
colon-derived organoids (Figure 4B) expressed genes of
differentiated cells (e.g., the goblet cell markers MUC1 and
MUC4 and the colonocyte marker CA2). Genes enriched in
tumor organoids included cancer-associated genes such as
PROX1, BAMBI, and PTCH1 and the Wnt target gene APCDD1
(Takahashi et al., 2002).
Several CRC classifications have been proposed based on
RNA expression. We combined expression data from organoid
samples and TCGA tissue samples and classified these in sub-
types using the gene signatures by Sadanandam et al. (2013).
Figure 4C displays the subtyping of the 22 organoid samples
and 431 TCGA RNA sequencing (RNA-seq) tumor tissue sam-
ples. The heatmap shows the normalized scores of genes by
samples, both sorted by subtype (see Experimental Proce-
dures). Organoid samples were spread across the subtypes,
with the transit-amplifying (TA) subtype being most frequently
represented. The enterocyte subtype was not represented. In
addition, the RNA expression data allowed expression analysis
Figure 3. Genomic Alterations Found in CRC Are Represented in Organoid Cultures
(A) Concordance of somatic mutations detected in organoid and corresponding biopsies. Bar graph represents the proportion of coding alterations that are
concordant between the biopsy and the corresponding organoid culture and those that are found only in organoid or biopsy specimen. N/A indicates cases in
which exome-sequencing was not performed on the corresponding biopsy.
(B) Overview of the mutations found in the tumor organoids. The hash-mark in each box represents each allele and whether it was subject to deletion, mutation,
frame-shift alteration, nonsense mutation or splice site mutation. Those alterations present in >10% of cases are compared to the percentage of cases reported
by the TCGA CRC. *Indicates discordant mutations targeting the same gene between the two sites in P19 and P24. See also Tables S1I and S1J.
(C) Somatic copy-number alterations in organoids among commonly amplified genes identified in TCGA CRC.
See also Figures S2 and S3 and Tables S1D–S1J.of individual genes in organoids. MLH1 expression was absent
from two tumor organoids from patient 19 as well as from patient
7 (that is also mutant in MSH3) (Figure S4). In the two tumor or-
ganoids from P24, we did not detect expression changes in
MLH1 or any other MSI-associated gene.
Effect of Porcupine Inhibitor on RNF43 Mutant
Organoids
Unlike most other WNT pathway mutations, RNF43 mutations
yield a cell that is hypersensitive to—yet still dependent on—
secreted WNT. Array data confirmed the expression of several
WNTs by the organoids (Figure S5A). The O-acyltransferase
Porcupine is required for the secretion of WNTs and its inhibition
prevents autocrine/paracrine activation of the pathway (Kado-
waki et al., 1996). The small molecule porcupine inhibitor IWP2
(Chen et al., 2009) was tested on a small panel of the tumor
organoids and strongly affected the RNF43 mutant P19b
organoid (Figure 5A). This observation implied that porcupine
inhibition may be evaluated for treatment of the small subset of
cancer patients mutant in RNF43.
Organoid Proof-of-Concept Drug Screen
Prompted by this, we developed a robotized drug sensitivity
screen in 3D-organoid culture and correlated drug sensitivity
with genomic features to identify molecular signatures associ-
ated with altered drug response. Organoid cultures were gently
disrupted and plated on BME-coated 384-well plates in a 2%BME solution. Organoids were left overnight before being
drugged and left for 6 days before measuring cell number using
CellTiter-Glo reagent. Drug sensitivity was represented by the
half-maximal inhibitory concentration (IC50), the slope of the
dose-response curve, and area under the dose-response curve
(AUC).
A bespoke 83 compound library was assembled for screening,
including drugs in clinical use (n = 25), chemotherapeutics (n =
10), drugs previously investigated in or currently undergoing
studies in clinical trials (n = 29), and experimental compounds
to a diverse range of cancer targets (n = 29) (Table S2A). The
library included the anti-EGFR antibody cetuximab, used clini-
cally forKRAS/NRAS/BRAFwild-type CRC, aswell as oxaliplatin
and 5-FU, first line chemotherapeutics for CRC treatment.
In total, 19 of 20 tumor organoids (from 18 different patients)
were successfully screened in experimental triplicate, gener-
ating >5,000 measurements of organoid-drug interactions
(Table S2B).
We incorporated a number of controls into the assay design.
The median Z factor score, a measure of assay plate quality,
across all screening plates was 0.62 (n = 119; upper and lower
quartile = 0.85 and 0.3, respectively), consistent with an experi-
mentally robust assay. We did observe some unexplained orga-
noid-specific variation in assay plate quality. Dose-response
measurements were performed in experimental triplicate or
duplicate (on separate plates) and replicate AUC values were
highly correlated (Pearson correlation [Rp] > 0.87) (Figure 5B).Cell 161, 933–945, May 7, 2015 ª2015 Elsevier Inc. 937
Figure 4. RNA Expression Analysis
(A) Correlation heat map of normal organoids
versus tumor organoids based on 2,186 genes
(the top 10% of genes in terms of SD). The normal
organoids are very highly correlated with each
other, whereas the tumor samples exhibit more
heterogeneity. The colors represent pairwise
Pearson correlations after the expression values
have been logged and mean-centered for every
gene. The hierarchical clustering is based on one
minus correlation distance. The affix N = normal,
T = tumor.
(B) MA plot of logged normal versus tumor
gene expression. p values are computed with the
R package limma, by comparing normal versus
tumor gene expression. Cancer-associated genes
(e.g., APCDD1, PROX1, and PTCH1) are shown
in the top half.
(C) CRC molecular subtypes are represented
by the organoid panel. Genes by samples heat
map of normalized gene expression of 22 organoid
samples and 431 TCGA RNA-seq tumor tissue
samples, organized by subtype. Within each
subtype, samples are sorted by their mean gene
expression for the signature genes associated with
that specific subtype.
See also Figure S4.
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Figure 5. Development of a High-Throughput Drug Screening Assay Utilizing Organoid Models
(A) Autocrine/paracrineWNT signaling in P19b. A small panel of tumor organoids was incubated with increasing amounts of the Porcupine inhibitor IWP2. Growth
of the RNF43mutant P19b was inhibited, indicative of dependency on autocrine/paracrine WNT signaling. Error bars indicate the SD of triplicate measurements.
See also Figure S5.
(B) Scatterplot of (1-AUC) values for all technical replicates of drug screening data. Plots show the correlation between the three different technical replicates and
each data point represents the (1-AUC) value for an individual organoid.
(C) Scatterplots of the correlation in (1-AUC) values for three compounds (GDC0941, obatoclax mesylate, and trametinib) screened twice during every screening
run. Values are the mean of three technical replicates.Furthermore, the compounds trametinib, GDC0941, and obato-
clax mesylate were screened twice independently on separate
assay plates and a good correlation was observed between
the experimentally determined AUC values (Rp = 0.79, 0.71,
and 0.76, respectively) (Figure 5C).
As a first validation, the only tumor organoid in the panel
that was sensitive to the Porcupine inhibitor LGK974 was P19b
(Figure S5B), confirming the observations made with IWP2
(Figure 5A). The clustering of compounds based on their IC50
values demonstrated a diverse range of sensitivities across the
organoids and identified three major sub-groups (Figure 6A).
One group was associated with sensitivity to a majority of the
compounds (organoids P8, P7, and P19a), in contrast to the
cluster (P31, P11) exhibiting insensitivity. The remaining organo-
ids had intermediate sensitivity. Interestingly, the multifocal
tumors P19a and P19b, derived from the same patient andboth carrying the BRAF V600E mutation, differed in their overall
drug response profile. We observed clustering of drugs that
inhibit the IGF1R and PI3K-AKT signaling pathways (Figure 6A),
and compounds with similar nominal targets had comparable
activity across the organoid collection. For example, a similar
sensitivity pattern was observed for the PI3K inhibitors GDC0941
and BYL719 (a-selective), the IGF1R inhibitors OSI-906 and
BMS-536924, EGFR inhibitors cetuximab and gefitinib, and
the BRAF inhibitors dabrafenib and PLX4720 (Figure 6B). All
but one of the organoids displayed a lack of sensitivity to
BRAF inhibition. P19a, a BRAF V600E mutant organoid, dis-
played partial sensitivity to dabrafenib with an IC50 of 0.5 mM,
comparable to IC50 values of BRAF V600E colorectal cancer
cell lines (range 0.004–2.55 mM; average 0.96 mM).
To identify genetic correlates between individual oncogenic
mutations and drug response, we performed a multivariateCell 161, 933–945, May 7, 2015 ª2015 Elsevier Inc. 939
(legend on next page)
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analysis of variance (MANOVA) incorporating IC50 values and
slopes of the corresponding dose-response curves, with MSI-
status as a covariate. Complete drug sensitivity and genomic
data sets were available for 18 organoids and used for this anal-
ysis. The analysis included 16 genes identified as mutated,
amplified, or deleted in CRC (referred to as mutant genes) as
described by Lawrence et al. (2014) (Table S3). The MANOVA
identified a subset (12 of 864, 1%) of gene-drug associations
as statistically significant (p < 0.005, incorporating a 30% false
discovery rate [FDR]) (Table S4). These results were further
filtered based on the magnitude of the effect size on the IC50
values of wild-type versus mutant cell line populations (effect
size >2; Cohen’s D), and correlations identified due to a singlet
outlier organoids were removed. This resulted in the identifica-
tion of one high confidence gene-drug association already re-
ported in the literature (Vassilev et al., 2004). Loss-of-function
mutations of the tumor suppressor TP53 were associated with
resistance to nutlin-3a (p = 0.0018), an inhibitor of MDM2 (Fig-
ure 7A). Of the four organoids that were wild-type for TP53 by
DNA sequencing, only P18 was (unexpectedly) insensitive to
nutlin-3a. However, immunohistochemistry of p53 in P18 re-
vealed the protein to be stabilized, indicative of functional inac-
tivation of the p53 pathway (Figure 7B).
We could also readily detect resistance to the anti-EGFR
inhibitors cetuximab and BIBW2992 (afatinib) in the setting of
KRAS mutant organoids (p = 0.008/FDR 37% and p = 0.029/
FDR 54%, respectively), although these associations were
below statistical significance when considering an FDR <30%
(Figures 7C and S6). Of the KRAS wild-type organoids, a subset
2/10 was insensitive to cetuximab, including P19b that has a
BRAF mutation, a known mediator of cetuximab resistance
(Di Nicolantonio et al., 2008). For the remaining organoid, further
mechanisms beyond mutated KRAS/NRAS/BRAF are likely
to be involved in cetuximab resistance (De Roock et al., 2010;
Vecchione, 2014).
We also identified a number of compounds with differential
activity in the absence of an apparent genetic biomarker (Fig-
ure 7D). For example, a subset of organoids was exquisitely sen-
sitive to the AKT1/2 inhibitor MK2206. Similarly, we observed
distinct subsets of organoids that are exquisitely sensitive to
the pan-ERBB inhibitor AZD8931 and the chemotherapeutic
gemcitabine. We also performed a validation screen with 11 of
the original 83 compounds across the organoid panel and
compared the measured responses (Figure S7; Table S5). We
observed positive correlation for all compounds and nine
exhibited good to fair reproducibility as indicated by an Rp of
0.5 or greater (Figures 7E and 7F). Variation within the assay
was likely due to inherent technical noise, biological variation,
and sensitivity to outlier data points due to the small number of
organoids.
In summary, the successful application of organoids in a
systematic and unbiased high-throughput drug screen toFigure 6. Heatmap of IC50s of All 85 Compounds against 19 Colorecta
(A) Organoids have been clustered based on their IC50 values across the drug pan
(B) Drugs with the same nominal targets have similar activity profiles across the
BYL719), IGF1R (OSI-906 and BMS-536924), EGFR (cetuximab and gefitinib), an
See also Tables S2A and S2B.identify clinically relevant biomarkers demonstrates the feasi-
bility and utility of organoid technology for investigating the
molecular basis of drug response. Furthermore, the identifica-
tion of putative novel molecular markers has opened avenues
for further investigation of drug sensitivity in CRC. The current
analysis is still constrained by the relatively small number of
patients. The derivation of a significantly larger organoid collec-
tion would increase the representation of rare genotypes
and the statistical power to detect molecular markers of drug
response.
DISCUSSION
Cancer cell lines have served for many years as the workhorse
model in cancer research. Recent studies have exploited high-
throughput screening of large panels of cancer cell lines to iden-
tify drug-sensitivity patterns and to correlate drug sensitivity to
genomic alterations (Barretina et al., 2012; Garnett et al.,
2012). From these high-throughput cell-line-based studies, a
picture emerges of a complex network of biological factors
that affect sensitivity to the majority of cancer drugs. For
instance, no direct relationship may exist between sensitivity
to a certain drug and a single genomic alteration. Instead, diffi-
cult-to-find, complex interactions between multiple genomic
alterations may determine drug sensitivity outcome. Thus, with
currently available insights, it remains a challenge to develop
algorithms that accurately predict the drug sensitivity of a
patient’s tumor based on the spectrum of genomic alterations
present, in the context of the unique genetic background.
Two approaches to determine directly the drug sensitivity in a
patient-derived sample have been quite widely exploited,
namely the short-term culture of tumor sections (Centenera
et al., 2013), and xeno-transplantation of the tumor into immuno-
deficient mice (Jin et al., 2010; Tentler et al., 2012). Short-term
culture allows for in vitro screening at a reasonably large scale,
but is constrained by the limited proliferative capacity of the cul-
tures. Xenotransplantation allows for in vivo screening but is
resource-intensive due to the need for large mouse colonies. It
thus appears of interest to develop additional technologies that
allow the combination of sequencing and high-throughput drug
screening in patient-derived samples. Here, we demonstrate
that the organoid culture platform can be exploited for genomic
and functional studies at the level of the individual patient at a
scale that cannot be achieved by existing approaches. Our
organoid drug screening assay generates reproducible high
quality drug sensitivity data, positive correlation of biological
replicates, and reproducible activity of compounds inhibiting
the same target. By connecting genetic and drug sensitivity
data, we were able to confirm the activity of cetuximab in a sub-
set of KRASwild-type organoids reflecting observations made in
the clinic (De Roock et al., 2010) as well as Nutlin-3a effective-
ness in TP53 wild-type organoids. Furthermore, we describel Cancer Organoids
el. The drug names and their nominal target(s) are provided in the bottom panel.
organoid panel. (1-AUC) values are plotted for inhibitor of PI3K (GDC0941 and
d BRAF (PLX4720 and dabrafenib).
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Figure 7. Gene-Drug Associations and Differential Drug Sensitivity Profiles of Interest
(A) Association of TP53mutational status with nutlin-3a response. Viability response curves of the altered (blue) and wild-type organoids (gray) as well as scatter
plots of cell line IC50 (mM) values are shown. IC50 values are on a natural logarithmic scale. Each circle represents one cell line, red bars indicate geometric means
of IC50 values and black bold bars indicate median log IC50 values. Box top/low bounds indicate upper/lower quartiles, and whiskers (indicated by the dashed
lines) extend to extreme values (minimal and maximal) excluding outliers (i.e., whose value is more than 3/2 times the upper quartile and less than 3/2 times the
lower quartile). Purple bar positions on the y axis indicate means +/ log IC50 SD.
(B) Immunohistochemical staining showing stabilization of TP53 in organoid P18. Scale bar, 100 mM.
(C) Association of KRAS status and cetuximab response. Colors and symbols coding is the same as (A).
(D) Dose-response curves after 6 days treatment with MK2206, AZD8931, and gemcitabine.
(E) Reproducibility of drug response profiles for 11 drugs. The Pearson correlation score of (1-AUC) values from the primary screen compared to (1-AUC) values
from validation screens are used for comparison. The validation screen was performed twice (run 1 and 2) with >1 month elapsed between each screen. NA, data
unavailable for this drug.
(F) The correlation of 1-AUC values from the primary and validation screens for AZD8931, gemcitabine, and nutlin-3a.
See also Figures S6 and S7 and Tables S3, S4, and S5.
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the differential activity of a handful of clinical and preclinical com-
pounds (gemcitabine, MK2206, and AZD8941).
Tumors are composed of a mixture of sub-clones that
coevolve through a Darwinian selection process. This cellular
heterogeneity and phenotypic variation allows the emergence
of a complex clonal architecture, which underpins important fea-
tures such as drug resistance and metastatic potential (Burrell
et al., 2013). Our CCF analysis of clonal structure determined
that almost all of the biopsies were polyclonal at the time of
resection, and this is reflected to varying extent in the corre-
sponding organoid culture. The ability to capture sub-clonal
populations in in vitro organoid culture should enable more
predictive modeling of patient responses to therapy. In many
respects, the clonal selection and heterogeneity observed in or-
ganoids is similar to PDX models of cancers (Eirew et al., 2015).
For both models, understanding the factors that affect tumor
heterogeneity and evolution, and how heterogeneity impacts
on drug response, will be important to fully exploit their potential
for predicting patient responses.
We perceive patient-derived organoids to be used to directly
test drug sensitivity of the tumor in a personalized treatment
approach. For this, we envision organoids to be tested against
a limited number of clinically approved drugs within weeks after
derivation. While building this pilot biobank, we observed that
normal epithelial tissue always yield good numbers of organoids
within weeks, while significant differences in ‘‘take rates’’ were
observed between patients’ tumor organoids. Crucial for this
approach to be effective, is to decrease the time needed to
derive and expand the organoids. In conclusion, tumor organo-
ids may fill the gap between cancer genetics and patient trials,
complement cell-line- and xenograft-based drug studies, and
allow personalized therapy design.
EXPERIMENTAL PROCEDURES
Human Tissues
Colonic tissues were obtained from The Diakonessen Hospital Utrecht with
informed consent and the study was approved by the ethical committee. All
patients were diagnosed with colorectal cancer. From the resected colon
segment, normal as well as tumor tissue was isolated. The isolation of healthy
crypts and tumor epithelium was performed essentially as described by Sato
et al. (2011).
Organoid Culture
Healthy tissue-derived organoids were cultured in Human Intestinal Stem
Cell medium (HISC). The composition of HISC is: Basal culture medium with
50% Wnt conditioned medium, 20% R-Spondin conditioned medium, 10%
Noggin conditioned medium, 13 B27, 1,25 mM n-Acetyl Cysteine, 10 mM
Nicotinamide, 50 ng/ml human EGF, 10 nM Gastrin, 500 nM A83-01, 3 uM
SB202190, 10 nM Prostaglandin E2, and 100 mg/ml Primocin (Vivogen). Tumor
organoids were cultured in HICS minus Wnt. See the Extended Experimental
Procedures for a detailed description.
Whole-Exome Sequencing and Copy-Number Analysis
For each sample, 250 ng of DNA was sheared and subject to whole-exome
sequencing using the Agilent v2 capture probe set and sequenced by
HiSeq2500 using 76 base pair reads, as previously described (Fisher et al.,
2011; Imielinski et al., 2012). A median 9.6 Gb of unique sequence was gener-
ated for each sample (Table S1A).
Sequence data were locally realigned to improve sensitivity and reduce
alignment artifacts prior to identification of mutations, insertions, and deletionsas previously described (Cibulskis et al., 2013; DePristo et al., 2011; Ojesina
et al., 2014).
Somatic copy-number analysis was performed using segmented copy-
number profiles generated from whole-exome sequencing using the SegSeq
algorithm (Table S1D) (Chiang et al., 2009). The procedure is described in detail
in the Extended Experimental Procedures.
Organoid Data Processing
RNA from 22 organoid tumor samples and 15 paired normal samples was
hybridized on Affymetrix Human Gene 2.0 ST arrays. The raw CEL files were
processed with Affymetrix Power Tools using the Hg19 genome build and
NetAffx annotation dating from 09-30-2012. Between-array normalization
was performed using rma-sketch, within APT. This resulted in an intensity
matrix of 21,681 genes by 37 samples. For analysis of individual genes, data
were analyzed using the R2 web application, which is freely available at
http://r2.amc.nl.
To subtype the samples, we used the gene signature published by
Sadanandamet al. (2013). The procedure is described in detail in the Extended
Experimental Procedures.
Organoid Viability Assays
Eight microliters of 7 mg/ml BME was dispensed in to 384-well microplates
and allowed to polymerize. Organoids were mechanically dissociated by
pipetting before being resuspended in 2% BME/growth media (15–20,000 or-
ganoids/ml) and dispensed into drug wells. The following day a 5-point 4-fold
dilution series of each compoundwas dispensed using liquid handling robotics
and cell viability assayed using CellTiter-Glo (Promega) following 6 days
of drug incubation. All screening plates were subjected to stringent quality
control measures and a Z factor score comparing negative and positive control
wells calculated. Dose-response curves were fitted to the luminescent signal
intensities utilizing a method previously described (Garnett et al., 2012).
Further information of the compounds used, data-fitting algorithm, and valida-
tion screen can be found in the Extended Experimental Procedures.
Systematic Multivariate Analysis of Variance
We excluded from the analysis drugs with no IC50 values falling within the
range of tested concentrations. For each of the remaining drugs, we assem-
bled an 183 2 matrix Y composed by two vectors of length n = 18, containing
IC50 values and dose-response curve slopes b, respectively, obtained by
treating 18 organoids with the drug under consideration. A multivariate
analysis of variance (MANOVA) model was then fitted to this drug response
data matrix with factors including the microsatellite stability status of the
organoids and the status (altered or wild-type) of 16 genomic features
(Extended Experimental Procedures). Significance and effect size scores
were obtained for each of the genomic-feature/drug pairs. Q values were
subsequently obtained by correcting the MANOVA p values for multiple
hypotheses testing, and a threshold of 30% of positive false discovery rate,
IC50, and effect size >2 (as quantified by the Cohen’s D) was used to identify
significant associations.
ACCESSION NUMBERS
The accession number for the healthy and tumor organoid array data reported
in this paper is GEO: GSE64392. The accession number for the single organoid
RNA-seq data is GEO: GSE65253.
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